Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 2
1998 3
2000 7
2001 5
2002 6
2003 2
2004 2
2005 5
2006 6
2007 6
2008 8
2009 10
2010 7
2011 2
2012 1
2013 2
2014 8
2015 11
2016 7
2017 1
2018 12
2019 8
2020 9
2021 16
2022 17
2023 16
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Panitumumab-induced trichomegaly.
Sütcüoğlu O, Özet A. Sütcüoğlu O, et al. Among authors: ozet a. Curr Probl Cancer. 2021 Dec;45(6):100748. doi: 10.1016/j.currproblcancer.2021.100748. Epub 2021 Apr 23. Curr Probl Cancer. 2021. PMID: 33933278 No abstract available.
Bone marrow involvement in breast cancer.
Sütcüoğlu O, Özdemir N, Yazıcı O, Özet A. Sütcüoğlu O, et al. Among authors: ozet a. Curr Probl Cancer. 2022 Feb;46(1):100785. doi: 10.1016/j.currproblcancer.2021.100785. Epub 2021 Aug 15. Curr Probl Cancer. 2022. PMID: 34417058 No abstract available.
Thirty-day mortality rates after immunotherapy initiation.
Sütcüoğlu O, İlhan A, Tacar SY, Güven DC, Uçar G, Karadurmuş N, Yıldız F, Eraslan E, Uncu D, Tural D, Üner A, Günel N, Özdemir N, Kılıçkap S, Öksüzoğlu ÖB, Özet A, Yazıcı O. Sütcüoğlu O, et al. Among authors: ozet a. Immunotherapy. 2021 Dec;13(17):1419-1426. doi: 10.2217/imt-2021-0082. Epub 2021 Oct 22. Immunotherapy. 2021. PMID: 34676791
Brigatinib-induced tuberculosis reactivation: A case report.
Keş V, Sütcüoğlu O, Gürler F, Yazıcı O, Özet A. Keş V, et al. Among authors: ozet a. Curr Probl Cancer. 2021 Dec;45(6):100738. doi: 10.1016/j.currproblcancer.2021.100738. Epub 2021 Apr 10. Curr Probl Cancer. 2021. PMID: 33867154
Niraparib-induced pure red cell aplasia.
Bir Yücel K, Yıldız S, Sütcüoglu O, Güvercin FS, Uyar Göçün P, Özdemir N, Yazıcı O, Özet A. Bir Yücel K, et al. Among authors: ozet a. J Oncol Pharm Pract. 2024 Jan;30(1):210-214. doi: 10.1177/10781552231197808. Epub 2023 Aug 29. J Oncol Pharm Pract. 2024. PMID: 37642988
Advances of Molecular Targeted Therapy in Gastric Cancer.
Cetin B, Gumusay O, Cengiz M, Ozet A. Cetin B, et al. Among authors: ozet a. J Gastrointest Cancer. 2016 Jun;47(2):125-34. doi: 10.1007/s12029-016-9806-8. J Gastrointest Cancer. 2016. PMID: 26875080 Review.
Combination therapies in non-clear-cell renal cell carcinoma.
Aslan V, Özdemir N, Yazıcı O, Özet A. Aslan V, et al. Among authors: ozet a. Lancet Oncol. 2023 Oct;24(10):e401. doi: 10.1016/S1470-2045(23)00393-5. Lancet Oncol. 2023. PMID: 37797639 No abstract available.
164 results